Urology

Featured Article

Urinary Tract Infections (UTI)

Multidrug-Resistant Bacteria Found in UTI Patient

Multidrug-Resistant Bacteria Found in UTI Patient

First case of colistin-resistant mcr-1 E coli in the United States; strains also have been identified in Europe and Canada.

Urology News

Latest Urology News

Urology Race, Procedure Type Influence Morbidity in Pediatric Surgery Patients

Race, Procedure Type Influence Morbidity in Pediatric Surgery Patients

Increased 30-day morbidity for black race, bladder and urinary diversion operations.

Bladder Cancer Early Recurrence After Laparoscopic Radical Cystectomy Explored

Early Recurrence After Laparoscopic Radical Cystectomy Explored

During first 24 months, 8.7% of patients with favorable pathological characteristics had progressed.

Prostate Cancer Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Tasquinimod Improves Radiographic Progression-Free Survival in mCRPC

Does not improve overall survival in metastatic castration-resistant prostate cancer.

Prostate Cancer PSA of 0.4 ng/mL Predicts PCa Progression

PSA of ≥0.4 ng/mL Predicts PCa Progression

Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.

Kidney Cancer Laparoscopic Nephrectomy May Be Performed as Outpatient Surgery

Laparoscopic Nephrectomy May Be Performed as Outpatient Surgery

Most patients discharged home within first 6 hours after surgery; none readmitted.

Overactive Bladder (OAB) Post-RP Radiation Therapy May Raise OAB Risk

Post-RP Radiation Therapy May Raise OAB Risk

De novo OAB — defined as urgency with or without frequency and nocturia — developed in some patients.

Overactive Bladder (OAB) Surgical Revision Rate 4% for Mesh-Based Prolapse Surgery

Surgical Revision Rate 4% for Mesh-Based Prolapse Surgery

Reoperation rate for transvaginal mesh prolapse surgery is 4%.

Prostate Cancer Midlife PSA Levels Predict Lethal Prostate Cancer

Midlife PSA Levels Predict Lethal Prostate Cancer

The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.

Erectile Dysfunction (ED) Uptick in Melanoma Risk With PDE5 Inhibitors

Uptick in Melanoma Risk With PDE5 Inhibitors

Researchers say skin cancer in these patients is likely due to more sun exposure.

Urology Patient Experience Has Limited Impact on GU Cancer Surgery Outcomes

Patient Experience Has Limited Impact on GU Cancer Surgery Outcomes

Patients treated in high-performing hospitals face fewer incidences of prolonged hospitalization or nursing-sensitive complications.

Bladder Cancer Gender Differences in Chemotherapy for Stage IV Bladder Cancer

Gender Differences in Chemotherapy for Stage IV Bladder Cancer

Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.

Urology Record Numbers of Americans Are Cancer Survivors

Record Numbers of Americans Are Cancer Survivors

More effective tools are needed to support the long-term recovery of patients who survive cancer.

Prostate Cancer Many Terminal Cancer Patients Still Receive Aggressive Treatment

Many Terminal Cancer Patients Still Receive Aggressive Treatment

Three in 4 young or middle-aged patients receive aggressive therapies in the last months of life.

Prostate Cancer Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.

Prostate Cancer TRUS-biopsy Inferior for Prostate Cancer Detection

TRUS-biopsy Inferior for Prostate Cancer Detection

Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.

Prostate Cancer Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Enzalutamide-Abiraterone-Leuprolide Ineffective for Localized PCa

Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.

Bladder Cancer Immunotherapy Helps Advanced Bladder Cancer Patients

Immunotherapy Helps Advanced Bladder Cancer Patients

About a quarter of older patients deemed too frail for chemo responded to atezolizumab.

Kidney Cancer Cabozantinib Shows Superiority in Treating Advanced mRCC

Cabozantinib Shows Superiority in Treating Advanced mRCC

The drug significantly improves overall and progression-free survival compared with everolimus, researchers report.

Prostate Cancer Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.

Prostate Cancer Factors Affecting Post-Brachytherapy Urinary Incontinence Type ID'd

Factors Affecting Post-Brachytherapy Urinary Incontinence Type ID'd

TURP and EBRT after seed implantation are associated with development of urge urinary incontinence.